Where to participate on the chain

The brief asks whether substrate-only participation is economically sufficient. It is not, and the arithmetic is short enough to state directly.

Medical printed circuits in mass production run $2 to $12 per unit, with medical flex commanding a 30% to 40% premium over standard applications. At $3 of content per unit, $350M of revenue requires about 120 million units a year. At $0.10 per unit, which is what a printed ECG electrode is worth, it requires 3.5 billion.

Worked through for CGM, the segment with the most units of any candidate:

The electrode pool for the whole world is a quarter of the revenue target, and almost none of it is for sale. This is the clearest available demonstration that substrate-only participation cannot work: even at 100% share of every flexible CGM electrode made anywhere, MERIDIAN would book $92M.

Moving up one stage to the module multiplies the content by eight. That is the argument for module participation, and it is why the recommendation is a run of two stages rather than one.

Reachable pools across the portfolio, all restated at 2029 so they are comparable to each other and to the target:

Every pool below is stated at what MERIDIAN would be paid, not at what the device sells for. That distinction is worth more than any other number in this section. A disposable ECG electrode sells for about $0.30 and a contract manufacturer is paid about $0.06 of it; a return electrode sells for about $2.00 and a supplier is paid about $0.60. Sizing these pools at selling prices, which is how the market-research figures come, would overstate what is available to MERIDIAN by roughly a factor of three.

Each segment is grown at its own reported rate from its own base year rather than at a single blended rate, because the rates across these segments run from 4.7% to 14.9% and a blend applied uniformly moves the largest line most.

One segment is deliberately absent. Point-of-care diagnostic cartridges are the best capability fit in the entire candidate set, and no cartridge unit volume was established within this analysis. The merchant evidence that does exist concerns who manufactures the whole fluidic cartridge, which is a different question from who supplies the electrode film inside it. Rather than carry an unsupported figure under the largest part of the module pool, it is excluded from every total here and recorded as an unsized opportunity. Sizing it is a first-stage task, and any plausible volume improves the case.

Of the total, 52% is commodity printed electrode work. The volume is in the low-margin half and the margin is in the small half, which is the structural shape of this opportunity and the reason the blended margin lands where it does.

The target would require 47.8% of everything reachable. If the pools are 20% smaller than estimated, it requires 59.7%. Those are not shares a new entrant takes; they are shares a monopolist holds.

One figure inside that total deserves flagging because it carries more than any other and rests on less. The merchant share of disposable ECG electrode work is set at 20%, and that figure is an estimate with no source behind it. It produces $159.2M, which is 22% of the reachable pool, and $47.8M of the private-label line. At 10% both halve. It is the largest untested number in the sizing, and testing it costs almost nothing. This is the single largest untested number in the sizing, and testing it costs almost nothing, which is why it is in the test program.